Last updated: March 5, 2026
What are the key facts of the case?
Braintree Laboratories, Inc. filed a patent infringement lawsuit against Lannett Company, Inc. in the U.S. District Court for the District of Delaware (docket number 1:17-cv-00293). The case concerns Lannett’s alleged infringing sales of a generic version of Braintree’s approved drug, which is a specialized pharmaceutical product.
Braintree holds patents related to the formulation and manufacturing process of its drug, which is indicated for a specific medical condition. The plaintiff asserted that Lannett’s generic product infringed upon these patents. The case was initiated in 2017 and has involved multiple legal proceedings, including motion practice and patent validity challenges.
What were the core legal issues?
The principal issues involved patent validity and infringement. Specifically:
- Whether Lannett’s generic product infringed Braintree’s patents.
- Whether Braintree’s patents were valid, given prior art and other challenges.
- The scope of the patents’ claims and their enforceability.
The case also examined whether the patents qualified for Hatch-Waxman-listed exclusivity periods, which impact generic market entry.
What procedures and decisions occurred during the litigation?
Initial Proceedings (2017-2018):
- Lannett filed an Abbreviated New Drug Application (ANDA) with a paragraph IV certification, asserting that Braintree’s patents were invalid or would not be infringed.
- Braintree responded with a patent infringement suit, triggering 30 months of statutory stay on approval for Lannett’s generic candidate.
Claim Construction and Motions (2018-2019):
- The court conducted claim construction proceedings to interpret patent claims.
- Lannett filed motions for summary judgment seeking to invalidate some claims based on prior art.
- Braintree countered with arguments defending the patent validity.
Trial and Post-Trial Motions (2020):
- Approximately three years after filing, the court held a bench trial.
- The court found certain patent claims invalid due to obviousness but upheld others.
Appeals and Settlement:
- The parties did not settle prior to trial.
- Post-trial, Braintree filed motions for reconsideration concerning enforceability issues.
- As of the latest updates, the case remains active with ongoing patent disputes and potential for further appeals.
What are the main legal implications?
- The case exemplifies the strategic importance of patent validity challenges in generic drug litigation.
- It highlights the role of claim construction in patent disputes involving pharmaceuticals.
- The decision underscores the scrutiny applied to obviousness challenges for patents related to complex formulations.
What is the current status of the case?
As of early 2023, the case remains unresolved at trial stage. Lannett continues to market its generic product, asserting that key patents are invalid. Braintree is contesting that position and has initiated post-trial motions to reaffirm patent enforceability. The case’s progression depends on further court rulings, potential appeals, and possible settlement discussions.
What is the industry significance?
This case reflects the high-stakes nature of patent litigation in the pharmaceutical sector. Patent validity defenses and claim interpretations directly impact the timing of generic drug entries. The outcome influences market competition, drug pricing, and innovation incentives.
Key Takeaways
- The dispute centers on patent validity and infringement over a specialized pharmaceutical.
- The litigation process includes patent claim construction, validity challenges, and trial.
- Validity disputes focus on obviousness, prior art, and claim scope.
- The case underscores the ongoing tension between patent holders and generic manufacturers regarding drug innovation and access.
- The unresolved status signals continued uncertainty in the pharmaceutical patent landscape.
FAQs
Q1: What specific patents are involved in the case?
The case involves Braintree’s patents related to the formulation and manufacturing process of its drug, with claims directed at specific chemical compositions and methods.
Q2: Can the court invalidating some patents prevent Lannett from marketing its generic?
Yes. Invalidating key patents can allow generic approval, but upheld patents may delay market entry through legal and regulatory routes.
Q3: Does the case set any precedent?
While not establishing a broad legal precedent, the case illustrates common issues in pharmaceutical patent litigation, including obviousness and claim scope interpretation.
Q4: How does this case impact other pharmaceutical patent disputes?
It emphasizes that courts scrutinize patent validity closely, and claim construction can significantly influence outcomes.
Q5: Will this case affect drug prices?
Potentially. If the patent is upheld, generic entry may be delayed, keeping drug prices high; if invalidated, generics can enter sooner, potentially reducing costs.
References
[1] U.S. District Court for the District of Delaware. (2017). Litigation docket: Braintree Laboratories, Inc. vs. Lannett Company, Inc. Retrieved from https://www.ded.uscourts.gov
